Impact of COX Inhibitors in Women's Health Initiative Hormone Trials
Author Information
Author(s): Hsia Judith, Manson JoAnn E, Kuller Lewis, Pettinger Mary, Choe John H, Langer Robert D, Limacher Marian, Oberman Albert, Ockene Judith, O'Sullivan Mary Jo, Robinson Jennifer G
Primary Institution: George Washington University
Hypothesis
Cyclooxygenase (COX) inhibitor use might have counteracted a beneficial effect of postmenopausal hormone therapy.
Conclusion
Use of COX inhibitors did not significantly affect the Women's Health Initiative hormone trial results.
Supporting Evidence
- The hormone trials enrolled 27,347 postmenopausal women.
- The trials were conducted at 40 clinical sites in the United States.
- COX inhibitor use did not significantly modulate the effect of hormone therapy on coronary risk.
- Results showed similar cardiovascular outcomes among users and non-users of NSAIDs.
Takeaway
The study looked at whether pain medications called COX inhibitors changed the effects of hormone therapy in older women, and found they didn't.
Methodology
The study was a secondary analysis of randomized, double-blind, placebo-controlled trials assessing hormone therapy effects on coronary risk.
Limitations
Use of COX-2 inhibitors was low, limiting the ability to test their specific effects.
Participant Demographics
Postmenopausal women aged 50–79 years.
Statistical Information
Confidence Interval
95% confidence interval 0.68–1.89 for non-users of COX inhibitors.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website